Trial Profile
A Randomized, Double-blind, Placebo-controlled, First-in-human, Study of Orally Administered AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Aug 2018
Price :
$35
*
At a glance
- Drugs JNJ-5806 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; First in man
- Sponsors Alios BioPharma
- 26 Jul 2018 Results published in the Journal of Infectious Diseases
- 10 Oct 2017 Status changed from recruiting to completed.
- 24 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.